NASD · Healthcare · Biotechnology · Denmark
Genmab ADR is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Genmab ADR stock.
Overvalued: intrinsic value $41.94 per share, market price $57.06, margin of safety -36.0% (as of 2026-10-30).
Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $41.94; the price of $57.06 is 36% above that value, and 78% of that value comes from beyond year five.
Leak Score: 22/100 on 7 of 12 signals (On Watch).
2 more funds hold it; the full list is part of the paid plan.
35 more in this industry show a wider margin of safety.
GMAB is overvalued (as of the 2026-10-30 close). Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $41.94; the price of $57.06 is 36% above that value, and 78% of that value comes from beyond year five.
$41.94 per share (as of the 2026-10-30 close), against a market price of $57.06. That is a margin of safety of -36.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
22 out of 100, which we rate "On Watch", on 7 of 12 value investing signals.